Related Experiment Video

Updated: Dec 22, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K

Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer

Tibor Szarvas1,2, Anita Csizmarik1, Nikolett Nagy1

  • 1Általános Orvostudományi Kar, Urológiai Klinika,Semmelweis Egyetem Budapest, Üllői út 78/B, 1082.

Orvosi Hetilap
|May 5, 2020
PubMed

Insights

New treatments for castration-resistant prostate cancer (CRPC) complicate therapy choices. Understanding resistance mechanisms, like MDR protein expression and AR alterations, enables rational treatment selection for CRPC patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Several novel drugs for castration-resistant prostate cancer (CRPC) have emerged, increasing treatment complexity.
  • Therapeutic decisions require individual optimization of selection, timing, and sequencing.
  • Resistance to novel therapies, including cross-resistance, has been observed.

Purpose of the Study:

  • To review resistance mechanisms against common systemic treatments for metastatic CRPC.
  • To highlight the shift towards rational-based treatment decisions from empiric approaches.

Main Methods:

  • Literature review of resistance mechanisms in metastatic CRPC.
  • Focus on docetaxel, abiraterone, and enzalutamide treatments.

Main Results:

  • Resistance mechanisms include multidrug-resistant (MDR) protein expression.
  • Alterations in androgen receptor (AR), Wnt, p53, and DNA-repair pathways (BRCA/ATM) contribute to resistance.
  • Therapy-induced neuroendocrine differentiation also drives resistance.

Conclusions:

  • Understanding resistance mechanisms is crucial for rational therapeutic decision-making in CRPC.
  • Personalized treatment strategies are needed to overcome resistance and optimize outcomes in CRPC.
Keywords:
kasztrációrezisztens prosztatarákterápiarezisztenciadocetaxelenzalutamidabirateroncastration-resistant prostate cancertherapy resistanceenzalutamideabiraterone

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.9K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.3K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K